Nanobiotix S.A.
HealthcareNASDAQ:NBTX · NASDAQ Global Select
+$0.21 today
Vol 0.08M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
28.4%
avg 403.0%
ROIC
-74.3%
avg -122.8%
ROA
-35.4%
avg -62.1%
Analysis
ROE is currently the strongest return metric at 28.4% versus its period average of 403.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | $974,060.00 | — | 53 | — | — |
Louis Kayitalire | Chief Medical Officer & Member of Executive Board | $695,358.00 | — | 67 | — | — |
Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | $691,941.00 | — | 52 | — | — |
Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | $477,762.00 | — | 52 | — | — |
Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | — | — | — | — | — |
Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | — | — | — | — | — |
Margaret Galluzzi | Vice President & Global Head of Clinical Operations | — | — | — | — | — |
Earl J. Bergey | Co-Founder | — | — | 71 | — | — |
Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +60.5% | +24.3% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +60.5% over three years. Forward estimates point to Revenue at +24.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
GH Research PLC
NASDAQ:GHRS
$1.45B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
Who manages NBTX?
Nanobiotix S.A. (NBTX) lists 9 active executives. The top listed executive is Brandon Owens, Vice President of Strategic Marketing & Corporate Communication.
Explore More
Continue the stock analysis
Jump to another research area for this company.